MOUNTAIN VIEW, Calif. NASA Ames Research Center, Moffett Field, CA – April 27, 2015 – Scanadu Inc., the Silicon Valley based medtech company that is building a family of mobile medical products for consumers, today announced that it has received $35 million in Series B funding to help further its vision to put the diagnostic power of a hospital in our smartphones. The funding round was led by Fosun International and Tencent Holdings Limited, with participation from China Broadband Capital and Iglobe Partners of Singapore, as well as A-round investors Relay Ventures, Redmile Group, Ame Cloud Ventures and Three Leaf Ventures, an affiliate of The Broe Group. With this round, Scanadu has raised $49.7 million in total funding to date.
“We continue to build out our family of products and move down the path to regulatory clearance in the U.S. and China,” said Scanadu founder and CEO Walter De Brouwer. “Scanadu’s mission has always been to give eight billion people access to quality healthcare via their smartphones.”
This month Scanadu will complete shipment of their first set of investigational Scanadu Scout™ devices to their more than 8,000 Indiegogo supporters. The device measures for heart rate, core body temperature, blood oxygenation, and cuffless and calibration-free systolic and diastolic blood pressure in one scan in seconds, and shares those results to an app on Android and iOS smartphones. Scanadu is currently working toward FDA submission and approval for that device, as well as Scanadu Urine (formerly known as ScanaFlo), an at-home urine test that similarly shares important health data to your smartphone.
"Fosun built Fosun Shanghai pharmaceutical’s business from the ground up, and we have long been committed to innovations in healthcare,” said Guao Guanchang, chairman of Fosun International. “When we looked at Scanadu, we saw a company solving a problem that affects virtually everyone. Our investment in Scanadu aligns with our deep interest in leveraging the magic of the mobile Internet to improve ties across the hospital, pharmaceutical and health insurance industries.”
"Advances in health technology are bringing powerful capabilities to understand our bodies via our smart phones. These trends will revolutionize health care over the long-term,” said David Wallerstein, chief eXploration officer and senior executive vice president of Tencent Holdings Limited. “Scanadu is leading this trend with innovative and consumer-friendly diagnostic products that deeply leverage the power of smart phone and cloud technologies. We're excited to join the Scanadu team on this journey."
New investors include:
Fosun International, often called the Berkshire Hathaway of China, is the largest privately-owned conglomerate in Mainland China (US$88 billion). Fosun has concentrated assets in hospitals, pharma companies and health insurance companies in China and is expanding its investment business globally.
Tencent Holdings Limited is a leading provider of Internet services in China. Tencent’s diversified services include QQ, Weixin/ WeChat for communications; Qzone for social networking; QQ Game Platform for online games; QQ.com and Tencent News app for information and Tencent Video app for video content.
China Broadband Capital (CBC) is a China-based venture capital fund focused on TMT (telecommunication, media and technology) innovations both in China and globally. Besides its active investments in China, CBC’s cross-border investment initiative brought Evernote and LinkedIn to China. CBC manages three US dollar funds and a Renminbi fund with total AUM of over $1 billion.
iGlobe Partners is a leading Asia Pacific Venture Capital firm headquartered in Singapore, with presence in Silicon Valley and Shanghai. With decades of technology investment experience and deep cross-border expertise, iGlobe is in a unique position to organize international investment syndicates, having guided portfolio companies over multiple business cycles, to scale their business globally to successful exits.
Scanadu also recently expanded its Board of Directors. New appointees include:
Dr. Robert Harrington, MD – Arthur L. Bloomfield Professor of Medicine and Chair of the Department of Medicine at Stanford University, Dr. Harrington is board certified in internal medicine and cardiovascular disease and a member of the board of directors of the American Heart Association.
Ezra Kucharz – President of Local Digital Media at CBS Corporation Inc., Mr. Kucharz began his career with NASA and has since founded, built and scaled a number of digital media businesses.
Based at NASA-Ames Research Center, Scanadu is using mobile and sensor technology to develop a portfolio of FDA approved, consumer friendly products that put the experience of an emergency room in the palm of your hand. Unveiled in November 2012, the company is working to ensure this is the last generation to know so little about our health. The product portfolio includes the Scanadu Scout vital sign monitor and Scanadu Urine, a urine analysis test. In July 2013, Scanadu became the most funded campaign on Indiegogo, enlisting supporters to be a part of the first usability study, followed by clinical studies for the company’s road to FDA approval. Scanadu was founded by Walter de Brouwer in 2011 and is a finalist in the Qualcomm Tricorder XPRIZE. For more information visit www.Scanadu.com.
1Qualcomm is a trademark of Qualcomm Incorporated, registered in the United States and other countries. STAR TREK, TRICORDER and related marks and logos are trademarks of CBS Studios Inc. Used under license.
April 15, 2015. MOUNTAIN VIEW, Calif. NASA Ames Research Center
Scanadu Inc., the Silicon Valley-based medtech company, today announced that Qualcomm Tricorder XPRIZE finalist teams Scanadu, led by Walter de Brouwer, CEO of Scanadu, and zensor, led by Jim McLaughlin, CTO of Intelesens and Director at NIBEC - University of Ulster, have joined forces to create Team Scanadu/Intelesens. The move brings together complementary expertise from both teams in their continued quest for the $10M Qualcomm Tricorder XPRIZE, a 3.5-year global competition sponsored by the Qualcomm Foundation, in which teams develop a consumer-focused, mobile device much like the medical Tricorder of Star Trek® fame, moving it from science fiction to science reality.
“The challenge we are trying to solve for the Qualcomm Tricorder XPRIZE competition is an extremely difficult one, and one that requires enormous effort and collaboration,” said Walter de Brouwer, CEO of Scanadu. “What first attracted us to the competition was the promise of bringing together some of the brightest minds in the world to create a device that could give consumers access to their own health data, and we are thrilled to join forces with team zensor for the remainder of the competition to achieve this incredible feat together.”
“In the space of wearable medical technology, there is a convergence of traditional medical devices and consumer products, in more and more areas of functionality,” said Jim McLaughlin, CTO of Intelesens and Director at NIBEC - University of Ulster. “By working together and playing on each other’s strengths, team Scanadu/Intelesensexpects to bring the reliability and accuracy of many areas of the medical device industry to the fast-paced world of the consumer.”
Scanadu and zensor were both announced as Qualcomm Tricorder XPRIZE finalist teams back in August 2014. To win this prize, teams must successfully create a device capable of diagnosing and interpreting a set of 15 medical conditions and capturing five vital health metrics. As part of the final round, teams will compete in both diagnostic experience evaluations and consumer testing at the University of California, San Diego’s Clinical and Translational Research Institute (CTRI), slated to begin in June 2015. The final judging and awards ceremony is scheduled to take place in early 2016.
Based at NASA-Ames Research Center, Scanadu is using mobile and sensor technology to develop a portfolio of FDA approved, consumer friendly products that put the experience of an emergency room in the palm of your hand. Unveiled in November 2012, the company is working to ensure this is the last generation to know so little about our health. The product portfolio includes the Scanadu Scout vital sign monitor and Scanadu Urine, a urine analysis test. In July 2013, Scanadu became the most funded campaign on Indiegogo, enlisting supporters to be a part of the first usability study, followed by clinical studies for the company’s road to FDA approval. Scanadu was founded by Walter de Brouwer in 2011 and is a finalist for the Qualcomm Tricorder XPRIZE. For more information visitwww.Scanadu.com.
Based in Belfast, Northern Ireland, Intelesens is a highly innovative medical technology company selling the world's first intelligent, non-invasive, wireless vital signs monitoring device for use in remote patient monitoring telehealth applications. It is a spin-out of the University of Ulster and is funded via private and venture capital investment. The Company has assembled a world-class team of employees that have established Intelesens at the forefront of exciting developments in the growing remote patient monitoring market. Intelesens, which was founded in 2001, is one of the finalists in the Qualcomm Xprize Competition.
Qualcomm is a trademark of Qualcomm Incorporated, registered in the United States and other countries.
STAR TREK, TRICORDER and related marks and logos are trademarks of CBS Studios Inc. Used under license.
Personalized Health Company Establishes Medical Advisory Board; Set to Conduct First Clinical Trials
NASA Ames Research Center, Moffett Field, CA - November 12, 2013 - Scanadu, a personalized health electronics company working to make this the last generation to know so little about our health, today announced it has received $10.5 million in Series A funding. Relay Ventures led the round of funding with participation from Tony Hsieh’s VegasTechFund, Jerry Yang’s Ame Cloud Ventures and others with a track record in building disruptive companies of great value in the mobile, cloud, consumer and healthcare industries. This new round of funding will be used to support Scanadu’s go-to market strategy and manufacturing, continue its path to FDA approval and add talent to the team. The company also announced that it has formed a Medical Advisory Board and will conduct its first clinical trials at the Scripps Translational Science Institute.
“We focus on backing ambitious entrepreneurs who are using mobile computing to unlock opportunity and create new markets,” said Kevin Talbot, co-founder and managing partner of Relay Ventures. “Walter’s vision for the future of consumer healthcare is profound and Scanadu stands to make a lasting impact on an industry ripe for disruption.”
“Scanadu is right at the heart of the next generation of computing which combines mobility, sensors, cloud and big data,” said Jerry Yang, co-founder of Yahoo! and founding partner of Ame Cloud Ventures. “I am bullish on Scanadu and its potential to revolutionize the way we think about our health.”
In July of this year, Scanadu closed a crowdfunding campaign on Indiegogo that quickly became the most funded campaign in the platform’s history, raising more than $1.6 million. Those who participated in the campaign will be a crucial part of the company’s road to FDA approval by taking part on a voluntary basis in a usability study for the Scanadu Scout™ in 2014.
Other participating investors in the Series A round include Broe Group, Mindful Investors and Redmile Group. With this round, Scanadu has raised $14.7 million in funding to date.
Medical Advisory Board and First Clinical Trials Pave the Way to Market
Furthering the company on its path to market, Scanadu will conduct its first clinical trials for Scanadu Scout™ at the Scripps Translational Science Institute (STSI). Those studies will be conducted as part of the Wired for Health mobile trial, which includes patients who live with diabetes, hypertension and heart arrhythmia. This first baseline study will help design future controlled studies, and will be designed to empower adults via a Scanadu Scout™ to yield optimal blood pressure.
“The era of digital healthcare has arrived,” said Dr. Eric Topol, director of the STSI and chief academic officer for Scripps Health. “We are excited to bring Scanadu to Scripps to further the potential of this technology to improve lives.”
Scanadu’s newly established Medical Advisory Board comprises leaders with deep experience from across the medical, regulatory and research fields. These advisors, listed below, all have a stake in advancing consumer healthcare and will actively advise Scanadu on long-term strategy and facilitate the sharing of knowledge and innovation transfer between Scanadu and the larger research and medical communities.
“We are more determined than ever to make the first medical tricorder a reality,” said Scanadu founder and CEO Walter De Brouwer. “With the experience and expertise of this group of investors and advisors, we know we’re in the right position to take our vision all the way and put FDA approved devices in the hands of consumers.”
Scanadu is developing a portfolio of products that put the experience of an emergency room visit in the palm of your hand. Its first device, the Scanadu Scout™, is a vital sign monitor that analyzes, tracks and trends your vitals - temperature, respiratory rate, oximetry, ECG, systolic blood pressure and diastolic blood pressure - in 10 seconds. The company is also creating a disposable urine analysis testing platform, ScanaFlo, which works with your smartphone to offer a complete urine analysis test in minutes. Once FDA approved, it could also measure for pregnancy complications, pre-eclampisa, gestational diabetes, heart-related kidney problems and urinary tract infections.
The Scanadu Medical Advisory Board includes: • Ms. Megan Moynahan, former Assistant Director for Technology and Innovation at the FDA's Center for Devices and Radiological Health, and current Executive Director of the Institute for Functional Restoration • Jon Mogford PhD, former Deputy Director of the Defense Sciences Office at DARPA and vice chancellor for research for The Texas A&M University System • Dr. Paul A. Sobotka, former Chief Medical Officer Ardian Inc. and professor of medicine, division of cardiology The Ohio State University. • Dr. Jennifer Mieres, cardiologist North Shore-LIJ Health System and professor of cardiology and population health at Hofstra University • Dr. Steven Curley, professor, Department of Surgical Oncology, Baylor College of Medicine • Dr. Alan Greene, chief medical officer, Scanadu, and founding President of the Board of the Society for Participatory Medicine and former member of the clinical faculty at Stanford University School of Medicine • Dr. Brett Mensh, former assistant professor at Columbia University and research scientist at MIT
About Scanadu Based at NASA-Ames Research Center, Scanadu is using mobile and sensor technology to make the first medical tricorder and ensure this is the last generation to know so little about our health. Unveiled in November 2012, the company is developing a portfolio of FDA approved, consumer friendly products that put the experience of an emergency room in the palm of your hand. The portfolio includes the Scanadu Scout™ vital sign monitor and ScanaFlo, a urine analysis test. In July 2013, Scanadu became the most funded campaign on Indiegogo, enlisting supporters to be a part of the first usability study and then clinical studies for the company’s road to FDA approval. Scanadu was founded by Walter de Brouwer in 2011 and is competing in the Qualcomm Tricorder X Prize. For more information visit www.Scanadu.com.
Company Launches Indiegogo Campaign to Begin Building the Future Global Body of Health Data
NASA Ames Research Park, Moffett Field, CA - May 22, 2013 - Scanadu, a personalized health electronics company participating in the Qualcomm Tricorder X PRIZE, today announced it is one step closer to bringing the first medical tricorder™ to life. In addition to unveiling updates and refinements to Scanadu Scout™ and ScanaFlo™, the company has also launched an Indiegogo campaign, inviting supporters to reserve a first-edition Scanadu Scout™ and contribute to building the future global body of health data.
“We are in awe at the enthusiasm the community has shown for the Scanadu Scout since the prototype was first revealed six months ago. We get calls and emails everyday from parents, researchers, students and body hackers anxious to be part of the first generation of consumers to truly understand their own health,” said Scanadu Founder and CEO Walter de Brouwer. “We’ve pushed the envelope, had some key breakthroughs, and are ready to share this next iteration of the product with consumers.”
Scanadu Scout is a vital sign monitor that analyzes, tracks, and trends your vitals - temperature, respiratory rate, oximetry, ECG, systolic blood pressure, diastolic blood pressure, and stress - in 10 seconds. With encouraging feedback from the community, partners, and regulators, and a strong push from Scanadu’s engineers and researchers, the company has made three key breakthroughs:
Just like Spock, you can now scout someone else - an ailing parent or sick child. With this breakthrough, Scanadu made some key changes to the design. It is now circular in shape, with the sensors built into the front of the device.
You’ll be able to collect readings from Scanadu’s suite of products - including ScanaFlo - through a single integrated app. Seeing your comprehensive healthfeed allows for data fusion, and the potential to read more vitals such as cuffless, non-invasive blood pressure.
Increased computational power
Scanadu has added more horsepower to the device, taking it from 8-bit (the power of an Apple II) to 32-bit (the power of a smartphone). The new device is built on Micrium, NASA’s real-time operation system for SAM (Sample Analysis at Mars) on the Rover Curiosity.
The company also announced updates today to ScanaFlo, a low-cost tool that uses the smartphone as a urine analysis reader, and unveiled the first design of the product. The small white, disposable paddle with multi-colored test strips and a QR code built into the device tests for levels of glucose, protein, leukocytes, nitrates, blood, bilirubin, urobilinogen, specific gravity, and pH in urine. It will also test for pregnancy.
Scanadu has received its first batch of 6,000 paddles and is ready to begin clinical trials. The company anticipates submitting a 510(k) application to FDA in the beginning of July 2013. “Today’s urine tests are really hard to use and the results are not easy to interpret,” said Aaron Rowe, research director at Scanadu. “ScanaFlo will make it simple for pregnant women to monitor themselves for complications between appointments with their doctor.”
Lastly, starting today, supporters can reserve a first-edition Scanadu Scout on Indiegogo and be part of the exploratory community bringing to life the vision of making this the last generation to know so little about our health. As a participant in the Indiegogo campaign, supporters will be able to take part in a usability study and provide feedback on feasibility, usability, and consumer friendliness that will be a valuable part of Scanadu’s road to FDA.
The 30-day campaign will offer a variety of perks including regular updates from Scanadu, a limited edition Scanadu Scout, visits to NASA to spend the day as a citizen astronaut for a space medicine workshop, and a tour of NASA Ames Research Park. Scanadu will offer an early bird special of $149 for the device to the first 1,000 participants. Additional units will be made available at the anticipated retail price of $199. Additionally, two ScanaFlo paddles be included with each Scanadu Scout, which is expected to ship in Q1 2014. The devices on Indiegogo are not FDA approved.
STAR TREK, TRICORDER and related marks and logos are trademarks of CBS Studios Inc. used under license by the X PRIZE Foundation. Scanadu is a participant in the Qualcomm Tricorder X PRIZE competition.
Based at NASA-Ames Research Park, Scanadu is using mobile, sensor and social technology to ensure this is the last generation to know so little about our health. In November 2012, the company unveiled its product family consisting of the Scanadu Scout vital sign monitor, ScanaFlo urine analysis test and Project ScanaFlu saliva test. The first products look to disrupt home medicine and will be in market early 2014. Scanadu was founded by Walter de Brouwer in 2010 and is competing in the Qualcomm Tricorder X Prize. For more information visit www.Scanadu.com.
Scanadu Unveils Family of New Tools to Revolutionize Consumer Healthcare
NASA-Based Company Puts a Doctor in Your Pocket
NASA Ames Research Center, Moffett Field, CA - November 29, 2012 - Scanadu, a new personalized health electronics company, today unveiled the first three products in its family of consumer health tools: Scanadu SCOUT, Project ScanaFlu and Project ScanaFlo. Based at NASA-Ames Research Center, Scanadu is using mobile, sensor and social technology to ensure this is the last generation to know so little about our health. The newly introduced home diagnostic tools are set to be the biggest innovation in home medicine since the invention of the thermometer.
Founded in 2010 by Walter de Brouwer after a family medical emergency, Scanadu is using imaging and sound analysis, molecular diagnostics, data analytics and a suite of algorithms to create devices that offer a comprehensive, real-time picture of your health data. The company is also participating in the Qualcomm Tricorder X Prize, which looks to bring healthcare to the palm of your hand, as well as the Nokia Sensing X Challenge, which seeks to revolutionize digital healthcare.
“The thermometer, introduced in the 1800s, was the last great tool to revolutionize home healthcare,” said Walter de Brouwer, founder and CEO of Scanadu. “Consumers don’t have the tools they need to monitor their health and make informed decisions about when they’re actually sick and need to see a doctor. We want to empower consumers to take control of their health and give them direct access to their personal healthfeed.”
Scanadu Product Family
Scanadu SCOUT is a small, speedy and affordable device that puts vital health information at your fingertips. Simply hold Scanadu SCOUT to the temple, and in less than ten seconds it will accurately read more than five vital signs. Data collected by the Scanadu SCOUT is uploaded to the Scanadu smartphone app via Bluetooth to show:
Pulse transit time
Heart rate (pulse rate)
Electrical heart activity
Heart rate variability
Blood oxygenation (pulse oximetry)
“Scanadu SCOUT lets users explore the diagnostic abilities of a clinic and conveniently puts them in your smartphone for less than $150,” said de Brouwer. “It’s like having a doctor in your pocket.”
Scanadu also unveiled its low-cost and disposable early detection diagnostic tools - Project ScanaFlo and Project ScanaFlu - which are integrated with Scanadu’s smartphone app.
Project ScanaFlo is a low-cost tool that uses the smartphone as a urine analysis reader. Designed to be sold over-the-counter as a disposable cartridge, Project ScanaFlo will test for pregnancy complications, preeclampisa, gestational diabetes, kidney failure and urinary tract infections. For pregnant women, Project ScanaFlo will be the first to provide a healthfeed throughout the duration of a pregnancy.
Project ScanaFlu is a low-cost tool that uses the smartphone as a reader to assess cold-like symptoms quickly, removing the guess work from early diagnosis of upper respiratory infections. By testing saliva, the disposable cartridge will provide early detection for Strep A, Influenza A, Influenza B, Adenovirus and RSV.
Scanadu will introduce all three products to market by the end of 2013.
Creating Your Personal HealthFeed
Scanadu is empowering consumers with medical tools that educate in real time - as well as over time. With the Scanadu mobile app, consumers will be able to track their personal healthfeed to monitor personal vitals and averages and identify health stats and trends over time. This healthfeed will provide consumers with a better understanding of their health and create more informed conversations between patients and their healthcare providers.
“When it comes to health - averages don’t cut it. Vitals change throughout the day and vary from person to person, so it makes no sense to assume we are all the same,” said Dr. Alan Greene, Chief Medical Officer at Scanadu. “Health decision shouldn’t be based on averages, they should be based on a real, accurate and personalized healthfeed of data - which we now have the power to give to the consumer in the palm of their hand.”
Based at NASA-Ames Research Center, Scanadu is using mobile, sensor and social technology to ensure this is the last generation to know so little about their health. Its first products look to disrupt home medicine and will be in market by 2013. Scanadu was founded by Walter de Brouwer in 2010. For more information visit www.Scanadu.com.